Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients with Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study

    Summary
    EudraCT number
    2018-000338-36
    Trial protocol
    ES   DE   BE   PL   GB   NO   IT  
    Global end of trial date
    02 Sep 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    10 May 2024
    First version publication date
    10 May 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    IEDAT-03-2018
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03563053
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    US IND: 115929
    Sponsors
    Sponsor organisation name
    Erydel S.p.A.
    Sponsor organisation address
    Via Meucci, 3, Bresso, Italy, 20091
    Public contact
    Irene Maccabruni, Erydel S.p.A., imaccabruni@quincetx.com
    Scientific contact
    Irene Maccabruni , Erydel S.p.A., imaccabruni@quincetx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    02 Sep 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    02 Sep 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Sep 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale). Exploratory Objective: To evaluate the long-term effect of EDS-EP in treating central nervous system (CNS) symptoms, as measured by the “Modified” International Cooperative Ataxia Rating Scale (mICARS), and Clinical Global Impression of severity and change (CGI-S/C).
    Protection of trial subjects
    The study was conducted in accordance with the Helsinki Declaration and Good Clinical Practice. Any essential documents were archived as required by Good Clinical Practice and national regulations. Independent Ethics Committee approval and written informed consent were obtained prior to starting the study.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    12 Jun 2018
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    2 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 10
    Country: Number of subjects enrolled
    Spain: 11
    Country: Number of subjects enrolled
    Belgium: 3
    Country: Number of subjects enrolled
    Germany: 13
    Country: Number of subjects enrolled
    United States: 25
    Country: Number of subjects enrolled
    United Kingdom: 11
    Country: Number of subjects enrolled
    Italy: 2
    Country: Number of subjects enrolled
    Norway: 5
    Country: Number of subjects enrolled
    Tunisia: 7
    Country: Number of subjects enrolled
    India: 15
    Country: Number of subjects enrolled
    Australia: 2
    Worldwide total number of subjects
    104
    EEA total number of subjects
    44
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    69
    Adolescents (12-17 years)
    6
    Adults (18-64 years)
    29
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Out of a total of 108 patients who completed the full treatment period in the ATTeST- IEDAT-02 study, 104 patients were enrolled in the IEDAT-03-2018 study and comprised the Total Set. These patients signed the ICF, completed the ATTeST study assessments, and did not present safety contraindications prior continuation with the EryDex treatment.

    Pre-assignment
    Screening details
    All patients enrolled in this study have participated in Study ATTeST-IEDAT-02-2015, and there was no de novo enrollment of new patients. Patients meeting all selection criteria received monthly infusions of EDS-EP (dose range of ~14-22 mg DSP/infusion). If this dose of EDS-EP was not tolerated, the patient was discontinued from the study.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded
    Blinding implementation details
    It's a open label extension study, so no blinding was applicable.

    Arms
    Arm title
    EryDex treatment
    Arm description
    ~14-22 mg dexamethasone sodium phosphate (DSP) for 12 months. The duration of EryDex treatment could be extended further and continue until patients eventually withdrew consent, or the Investigator decided to discontinue treatment based on a risk / benefit assessment. EryDex System was a combination product that was used to load DSP into autologous erythrocytes (EDS) creating the EDS-end product. EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T. The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study.
    Arm type
    Experimental

    Investigational medicinal product name
    EryDex System treatment
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection/infusion
    Routes of administration
    Infusion
    Dosage and administration details
    EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T. EryDex treatment was administered monthly throughout the period of the study. The duration of EryDex treatment was planned for 12 months but could be extended further and continue until patients eventually withdrew consent, or the Investigator decided to discontinue treatment based on a risk / benefit assessment.

    Number of subjects in period 1
    EryDex treatment
    Started
    104
    Total Set
    104
    Safety Set
    104
    Full Analysis Set
    80
    Month 12
    64
    Month 24
    33
    Month 36
    21
    Month 48
    7
    Month 57
    1
    Completed
    0
    Not completed
    104
         Consent withdrawn by subject
    17
         Physician decision
    1
         Adverse event, non-fatal
    3
         Study terminated by the sponsor
    71
         Due to the COVID-19 pandemic
    12

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial (overall period)
    Reporting group description
    -

    Reporting group values
    Overall trial (overall period) Total
    Number of subjects
    104 104
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    69 69
        Adolescents (12-17 years)
    6 6
        Adults (18-64 years)
    29 29
        From 65-84 years
    0 0
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    11.4 ( 4.57 ) -
    Gender categorical
    Units: Subjects
        Female
    55 55
        Male
    49 49
    Subject analysis sets

    Subject analysis set title
    EryDex - FAS
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Full Analysis Set Population (FAS): the FAS comprised all patients who entered IEDAT-03-2018 study, had a Baseline Efficacy Assessment in IEDAT-03-2018 and who received at least one dose of study medication and had at least one post-Baseline Efficacy Assessment of the ICARS in this extension study.

    Subject analysis set title
    EryDex - Total Set
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    In this trial, the Total or Overall Set (N=104) numerically corresponds to the Safety set, which included all patients who provided informed consent or assent and who received any dose of study medication during ATTeST-IEDAT-03-2018 study (i.e., “Date performed” given on the “EDS-EP Infusion” eCRF page at any Visit).

    Subject analysis set title
    EryDex - SAF
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    The Safety Analysis Set consisted of all patients who provided informed consent or assent and who received any dose of study medication during IEDAT-03-2018 study. The Safety Analysis Set was used for all safety analyses.

    Subject analysis sets values
    EryDex - FAS EryDex - Total Set EryDex - SAF
    Number of subjects
    80
    104
    104
    Age categorical
    Units: Subjects
        In utero
    0
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
    0
        Newborns (0-27 days)
    0
    0
        Infants and toddlers (28 days-23 months)
    0
    0
        Children (2-11 years)
    69
    69
        Adolescents (12-17 years)
    6
    6
        Adults (18-64 years)
    29
    29
        From 65-84 years
    0
    0
        85 years and over
    0
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    ( )
    11.4 ( 4.57 )
    11.4 ( 4.57 )
    Gender categorical
    Units: Subjects
        Female
    55
    55
        Male
    49
    49

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    EryDex treatment
    Reporting group description
    ~14-22 mg dexamethasone sodium phosphate (DSP) for 12 months. The duration of EryDex treatment could be extended further and continue until patients eventually withdrew consent, or the Investigator decided to discontinue treatment based on a risk / benefit assessment. EryDex System was a combination product that was used to load DSP into autologous erythrocytes (EDS) creating the EDS-end product. EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T. The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study.

    Subject analysis set title
    EryDex - FAS
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Full Analysis Set Population (FAS): the FAS comprised all patients who entered IEDAT-03-2018 study, had a Baseline Efficacy Assessment in IEDAT-03-2018 and who received at least one dose of study medication and had at least one post-Baseline Efficacy Assessment of the ICARS in this extension study.

    Subject analysis set title
    EryDex - Total Set
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    In this trial, the Total or Overall Set (N=104) numerically corresponds to the Safety set, which included all patients who provided informed consent or assent and who received any dose of study medication during ATTeST-IEDAT-03-2018 study (i.e., “Date performed” given on the “EDS-EP Infusion” eCRF page at any Visit).

    Subject analysis set title
    EryDex - SAF
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    The Safety Analysis Set consisted of all patients who provided informed consent or assent and who received any dose of study medication during IEDAT-03-2018 study. The Safety Analysis Set was used for all safety analyses.

    Primary: Number of Treatment-Emergent Adverse Event (TEAE), treatment-emergent serious adverse events (TESAE), and adverse events of special interest (AESI) throughout the study

    Close Top of page
    End point title
    Number of Treatment-Emergent Adverse Event (TEAE), treatment-emergent serious adverse events (TESAE), and adverse events of special interest (AESI) throughout the study [1]
    End point description
    Assessment of TEAEs, treatment-emergent serious adverse events (TESAE), and adverse events of special interest (AESI) were performed throughout the study, from the time of signing of the ICF at Baseline Visit through to the Final Study Visit (Month 12 or early discontinuation). All patients were to be followed up through 30 days after the Final Visit (Month 12 or early discontinuation) or at least 60 days after the final infusion, whichever was longer.
    End point type
    Primary
    End point timeframe
    From Baseline (Visit 1 - Day 0) to Follow-up (~60 days after last infusion)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Not applicable.
    End point values
    EryDex - SAF
    Number of subjects analysed
    104
    Units: Number of events
    number (not applicable)
        Number of TEAEs
    1233
        Number of Serious TEAEs
    19
        Number of TEAE leading to Death
    0
        Number of TEAE leading to Permanent Withdrawal of
    5
        Adverse Events During COVID-19 Interruption - On D
    3
        Adverse Events During COVID-19 Interruption - Off
    3
        Adverse Events During COVID-19 Interruption - Rest
    55
        TEAE by Worst Intensity - Mild
    1029
        TEAE by Worst Intensity - Moderate
    187
        TEAE by Worst Intensity - Severe
    17
        TEAE by Closest Relationship to Treatment - Probab
    283
        TEAE by Closest Relationship to Treatment - Possib
    167
        TEAE by Closest Relationship to Treatment - Unlike
    178
        TEAE by Closest Relationship to Treatment - Not re
    604
        Number of AESI
    83
    No statistical analyses for this end point

    Secondary: Change From Baseline in Quality of Life Using EQ-5D-5L Scale to Month 54

    Close Top of page
    End point title
    Change From Baseline in Quality of Life Using EQ-5D-5L Scale to Month 54
    End point description
    The EQ-5D included single item measures of 5 health dimensions: - mobility, - self-care, - usual activities, - pain / discomfort, and - anxiety / depression. In addition, EQ-5D included a global rating of current health using a visual analogue scale (VAS) ranging from 0 (worst health imaginable) to 100 (best health imaginable). The EQ VAS provided a quantitative measure of the patient’s perception of their overall health. The EQ-5D-5L included five levels of severity (i.e., no problems, slight problems, moderate problems, severe problems, and extreme problems) for each of the five EQ-5D dimensions. These levels were scored from 1 = no problems to 5 = extreme problems: from 5, min/worst, to 25, best/max); EQ-VAS (EQ Visual Analogue scale) scoring from 0, min/worst, to 100, best/max. The efficacy data focus mainly up to Month 36 as afterwards the number of patients / assessments dropped below 20% of the initial sample size, which was required for the efficacy evaluations.
    End point type
    Secondary
    End point timeframe
    From Baseline (Visit 1- Day 0) to Month 36
    End point values
    EryDex - FAS
    Number of subjects analysed
    80 [2]
    Units: Score on a scale
    arithmetic mean (standard deviation)
        to Month 6
    0.015 ( 0.1131 )
        to Month 12
    -0.022 ( 0.1145 )
        to Month 18
    0.007 ( 0.1233 )
        to Month 24
    0.011 ( 0.1746 )
        to Month 30
    -0.021 ( 0.1117 )
        to Month 36
    0.011 ( 0.1242 )
    Notes
    [2] - Month 6 N=73, Month 12 N=61, Month 18 N=51, Month 24 N=32, Month 30 N=22, Month 36 N= 20
    No statistical analyses for this end point

    Secondary: Number of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C) From Baseline (Visit 1- Day 0) to Month 54

    Close Top of page
    End point title
    Number of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C) From Baseline (Visit 1- Day 0) to Month 54
    End point description
    The CGI-C scale assesses the change in the patient’s clinical status from baseline using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Clinicians were required to conduct a full clinical interview and examination of the patient. The interview and examination assessed various aspects of the patient’s appearance (grooming, evidence of falls, etc.), ataxia, cognition (orientation, calculation ability, language, ability to follow commands, memory, etc.), apraxia, dysarthria, extrapyramidal motor symptoms, activities of daily living, and mood. The higher the score the worse the outcome. The efficacy data focus mainly up to Month 36 as afterwards the number of patients / assessments dropped below 20% of the initial sample size, which was required for the efficacy evaluations.
    End point type
    Secondary
    End point timeframe
    From Baseline (Visit 1- Day 0) to Month 36
    End point values
    EryDex - FAS
    Number of subjects analysed
    80 [3]
    Units: Number of Patients
    number (not applicable)
        Month 6 - Improved (Score 1-3)
    9
        Month 6 - No change or Worsened (Score 4-7)
    68
        Month 12 - Improved (Score 1-3)
    14
        Month 12 - No change or Worsened (Score 4-7)
    45
        Month 18 - Improved (Score 1-3)
    6
        Month 18 - No change or Worsened (Score 4-7)
    41
        Month 24 - Improved (Score 1-3)
    5
        Month 24 - No change or Worsened (Score 4-7)
    26
        Month 30 - Improved (Score 1-3)
    2
        Month 30 - No change or Worsened (Score 4-7)
    17
        Month 36 - Improved (Score 1-3)
    3
        Month 36 - No change or Worsened (Score 4-7)
    16
    Notes
    [3] - Month 6 N=80, Month 12 N=59, Month 18 N=47, Month 24 N=29, Month 30 N=19, Month 36 N= 19
    No statistical analyses for this end point

    Secondary: Number of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT From Baseline (Visit 1 - Day 0) to Month 54

    Close Top of page
    End point title
    Number of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT From Baseline (Visit 1 - Day 0) to Month 54
    End point description
    The CGI-S scale measures global severity of illness at a given point in time, and is usually rated on a 7-point, Likert-type scale ranging from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). No version of the CGI-S exists which has been specifically adapted for use in patients with A-T; therefore, a 5-point version was developed that considered the severity of the following symptoms of A-T: ataxia (walking), dysarthria, dysmetria, extrapyramidal symptoms (chorea, myoclonus, dystonia, and tremor), and eye movements. Ratings of none (0), mild (1), moderate (2), severe (3), and very severe (4) were selected based on the level of symptomatology. The higher the score the worse the outcome. The efficacy data focus mainly up to Month 36 as afterwards the number of patients / assessments dropped below 20% of the initial sample size, which was required for the efficacy evaluations.
    End point type
    Secondary
    End point timeframe
    From Baseline (Visit 1- Day 0) to Month 36
    End point values
    EryDex - FAS
    Number of subjects analysed
    80 [4]
    Units: Number of Patients
    number (not applicable)
        Baseline - CGI-S Score - 0
    2
        Baseline - CGI-S Score - 1
    18
        Baseline - CGI-S Score - 2
    31
        Baseline - CGI-S Score - 3
    23
        Baseline - CGI-S Score - 4
    0
        Month 6 - CGI-S Score - 0
    1
        Month 6 - CGI-S Score - 1
    20
        Month 6 - CGI-S Score - 2
    30
        Month 6 - CGI-S Score - 3
    22
        Month 6 - CGI-S Score - 4
    3
        Month 12 - CGI-S Score - 0
    0
        Month 12 - CGI-S Score - 1
    12
        Month 12 - CGI-S Score - 2
    28
        Month 12 - CGI-S Score - 3
    17
        Month 12 - CGI-S Score - 4
    2
        Month 18 - CGI-S Score - 0
    0
        Month 18 - CGI-S Score - 1
    13
        Month 18 - CGI-S Score - 2
    21
        Month 18 - CGI-S Score - 3
    12
        Month 18 - CGI-S Score - 4
    1
        Month 24 - CGI-S Score - 0
    0
        Month 24 - CGI-S Score - 1
    10
        Month 24 - CGI-S Score - 2
    10
        Month 24 - CGI-S Score - 3
    9
        Month 24 - CGI-S Score - 4
    2
        Month 30 - CGI-S Score - 0
    0
        Month 30 - CGI-S Score - 1
    5
        Month 30 - CGI-S Score - 2
    10
        Month 30 - CGI-S Score - 3
    4
        Month 30 - CGI-S Score - 4
    0
        Month 36 - CGI-S Score - 0
    0
        Month 36 - CGI-S Score - 1
    3
        Month 36 - CGI-S Score - 2
    10
        Month 36 - CGI-S Score - 3
    6
        Month 36 - CGI-S Score - 4
    0
    Notes
    [4] - Baseline N=74,Month 6 N=76, Month 12 N=59, Month 18 N=47, Month 24 N=31, Month30 N=19, Month36 N= 19
    No statistical analyses for this end point

    Secondary: Change from baseline of the Modified International Cooperative Ataxia Rating Scale (mICARS) until month 54

    Close Top of page
    End point title
    Change from baseline of the Modified International Cooperative Ataxia Rating Scale (mICARS) until month 54
    End point description
    The International Cooperative Ataxia Rating Scale (ICARS) was an assessment of the degree of impairment in patients with cerebellar ataxia and was administered in its entirety; however, the primary efficacy assessment was based on the modified (m)ICARS, which excluded the Oculomotor domain (items 17 to 19) and items 8 to 12 of the Kinetic Functions domain of the ICARS. The mICARS was a 54 points maximum score (min 0) questionnaire divided into 3 sections: • Posture and Gait Disturbance section-7 items (min score 0, max score 34) • Kinetic Function-2 items (min 0, max 12) • Speech Disorder- 2 items (min 0, max 8). An higher scores - both for total and subscores - indicate a higher level of disease impairment. The subscores are added to give the total score. The efficacy data focus mainly up to Month 36 as afterwards the number of patients / assessments dropped below 20% of the initial sample size, which was required for the efficacy evaluations.
    End point type
    Secondary
    End point timeframe
    From Baseline (Visit 1- Day 0) to Month 36
    End point values
    EryDex - FAS
    Number of subjects analysed
    80 [5]
    Units: Score on a scale
    arithmetic mean (standard deviation)
        to Month 6
    0.7 ( 4.09 )
        to Month 12
    1.5 ( 3.36 )
        to Month 18
    2.7 ( 4.28 )
        to Month 24
    3.9 ( 4.96 )
        to Month 30
    4.5 ( 5.41 )
        to Month 36
    34.0 ( 5.17 )
    Notes
    [5] - Month 6 N=78, Month 12 N=60, Month 18 N=48, Month 24 N=32, Month 30 N=21, Month 36 N= 18
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    TEAEs were all the AEs reported from Baseline (Visit 1 - Day 0) to Follow-up (~60 days after the last infusion).
    Adverse event reporting additional description
    All AEs that occurred during this IEDAT-03-2018 study are defined as TEAEs, as all patients received EryDex treatment in the study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    22.0
    Reporting groups
    Reporting group title
    EryDex - SAF
    Reporting group description
    The Safety Analysis Set consisted of all patients who provided informed consent or assent and who received any dose of study medication during IEDAT-03-2018 study. The Safety Analysis Set was used for all safety analyses.

    Serious adverse events
    EryDex - SAF
    Total subjects affected by serious adverse events
         subjects affected / exposed
    12 / 104 (11.54%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    B-cell lymphoma
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hodgkin's disease
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Odontogenic cyst
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Forearm fracture
         subjects affected / exposed
    2 / 104 (1.92%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Surgical and medical procedures
    Gastrointestinal tube insertion
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Central nervous system lesion
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pharyngeal swelling
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Trombocytopenic Purpura
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Dysphagia
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Viral Infection
         subjects affected / exposed
    1 / 104 (0.96%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    EryDex - SAF
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    98 / 104 (94.23%)
    Investigations
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    6 / 104 (5.77%)
         occurrences all number
    8
    Coronavirus test positive
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    8
    Serum ferritin decreased
         subjects affected / exposed
    8 / 104 (7.69%)
         occurrences all number
    9
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin papilloma
         subjects affected / exposed
    8 / 104 (7.69%)
         occurrences all number
    10
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    10
    Infusion related reaction
         subjects affected / exposed
    28 / 104 (26.92%)
         occurrences all number
    199
    Nervous system disorders
    Headache
         subjects affected / exposed
    15 / 104 (14.42%)
         occurrences all number
    22
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    6 / 104 (5.77%)
         occurrences all number
    9
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    16 / 104 (15.38%)
         occurrences all number
    20
    Pyrexia
         subjects affected / exposed
    33 / 104 (31.73%)
         occurrences all number
    54
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    23 / 104 (22.12%)
         occurrences all number
    32
    Nausea
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    9
    Vomiting
         subjects affected / exposed
    20 / 104 (19.23%)
         occurrences all number
    38
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    19 / 104 (18.27%)
         occurrences all number
    42
    Epistaxis
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    10
    Rhinorrhoea
         subjects affected / exposed
    12 / 104 (11.54%)
         occurrences all number
    17
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    10
    Pruritus
         subjects affected / exposed
    7 / 104 (6.73%)
         occurrences all number
    7
    Rash
         subjects affected / exposed
    9 / 104 (8.65%)
         occurrences all number
    11
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    10 / 104 (9.62%)
         occurrences all number
    15
    Corona Virus Infection
         subjects affected / exposed
    17 / 104 (16.35%)
         occurrences all number
    19
    Nasopharyngitis
         subjects affected / exposed
    21 / 104 (20.19%)
         occurrences all number
    30
    Upper respiratory tract infection
         subjects affected / exposed
    23 / 104 (22.12%)
         occurrences all number
    36
    Urinary tract infection
         subjects affected / exposed
    6 / 104 (5.77%)
         occurrences all number
    7
    Product issues
    Product contamination
         subjects affected / exposed
    13 / 104 (12.50%)
         occurrences all number
    19
    Metabolism and nutrition disorders
    Iron deficiency
         subjects affected / exposed
    16 / 104 (15.38%)
         occurrences all number
    29

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Mar 2018
    • Revision of the study procedures to ensure that sterility is maintained throughout the collection of autologous blood cells, processing, administration, and testing (rapid testing, gram stain and culture) of EryDex treatment. • Addition of the reference to the document entitled “Study Procedures on Sterility Testing for Study IEDAT-03-2018 (Open Label Extension (OLE)-IEDAT)”. • Minor editorial changes have been made and additional clarifications provided, including a modification in the study's entry criteria to allow inclusion of patients that have not worsened significantly on treatment.
    30 Apr 2018
    • Provision of clarification explaining that the Principal Investigator, instead of the CRO, will decide if a patient is eligible to continue into the IEDAT-03-2018 study. • The removal of requirement that the patient cannot worsen significantly during treatment (e.g., evidence of disease stabilisation or improvement as determined by the ratings of the CGI-C) to be eligible for the IEDAT-03-2018 study, to avoid doubts regarding the exclusion of the placebo patients who might not show disease stabilisation or improvement. Therefore, it has been clarified that, to be eligible for the IEDAT-03-2018 study, patients must have completed 12 months of treatment in the ATTeST study, including all its study assessments, do not present safety contraindication to continuation of treatment, and provide informed consent.
    19 Mar 2019
    • CRO references were changed. • Safety e-mail was changed. • EryDel address was updated on the Sample Study Solutions and Medication Labels.
    29 Apr 2019
    • In the study design, the treatment period was changed from 12 months of treatment to full treatment period. • During the study, Long-term Efficacy Assessments were changed from a 6-month frequency to approximately every 6 months. • Rapid microbial detection test (Staining test) was removed. • The definition of the allowed treatment window was clarified: the monthly infusions should be performed every 21-28 days. A window of + 10 days was permitted for each of the scheduled Monthly Visits. Therefore, no EDS-EP infusion should be performed less than 21 days or more than 38 days after the previous infusion. The window between an infusion and the subsequent one should be kept as regular as possible throughout the study, avoiding fluctuations in administration windows. The date of an infusion is not bound to the date of the initial treatment but to the date of the previous IMP administration. • Exclusion Criterion #4 was changed and a value in case of oral candidiasis was added. More in details: - PREVIOUS version: CD4+ lymphocyte count < 400 / mm3 (for patients 6 years of age) or < 200 / mm3 (for patients > 6 years). - UPDATED version:CD4+ lymphocyte count < 400 / mm3 (for patients 6 years of age) or < 150 / mm3 (for patients > 6 years). In presence of oral infections, like oral candidiasis, documented at the screening or recurrent as per medical history documentation, the limit increases to < 200 / mm3 (for patients > 6 years). • The Microbial Staining test was removed.
    22 May 2020
    • The planned number of patients was updated to 155. • Timelines for the last patient in were updated. • Appendix 13 was added: Temporary changes to the Protocol implemented / to be implemented because of COVID-19 pandemic.
    01 Dec 2020
    • Study design and rationale were updated to allow patients who were discontinued from the ATTeST study during the COVID-19 pandemic to receive the EryDex treatment in the context of the IEDAT-03-2018 study. • Inclusion criterion #1 was revised to include patients discontinued the ATTEST study during the COVID-19 pandemic. • Visit assessments and schedule were amended to reflect the updated study design and inclusion criteria.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    India was particularly affected by COVID-19-dependent treatment and visit interruptions.This long interruption would have resulted in insufficient long-term safety data. For this reason, EryDel decided to discontinue the IEDAT-03-2018 study in India
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 05:06:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA